First clinical trials start with HIV mRNA vaccine, using Moderna's new corona vaccine technology

The new coronavirus vaccine provided by Modelna is

an mRNA vaccine that uses messenger RNA (mRNA), and although the technology has been developed for 30 years, it is also the first mRNA vaccine to be put into practical use along with the Pfizer vaccine. there was. Moderna and the International AIDS Vaccine Initiative (IAVI) have announced that they have begun clinical trials of a human immunodeficiency virus (HIV) vaccine using Modelna's mRNA vaccine technology.

Moderna --IAVI and Moderna Launch Trial of HIV Vaccine Antigens Delivered Through mRNA Technology

Moderna's HIV Vaccine Has Officially Begun Human Trials | them.

HIV inactivates antibody-producing B cells and infects and proliferates T cells , which are key to the immune system. Therefore, when infected with HIV, the immune system is extremely weakened, causing 'acquired immunodeficiency syndrome (AIDS, AIDS)' in which various infectious diseases are caused by pathogens that are not normally affected. Since HIV destroys the immune system itself, it is difficult to apply conventional vaccine technology, and antiretroviral therapy (ART), which suppresses viral replication in the body, is the mainstream.

In addition, pre-exposure prophylaxis (PrEP) is a treatment to prevent HIV infection, and in December 2021, the injection drug 'Cabotegravir' that reduces the risk of HIV infection was approved by the US Food and Drug Administration (FDA). However, PrEP is a medication and requires regular medication.

FDA approves world's first 'injection to prevent HIV infection'-GIGAZINE

Moderna's mRNA vaccine technology, which was also used in the new coronavirus vaccine, is applied to the vaccine that was clinically tested this time, with the aim of increasing the immunogen of HIV by mRNA and preventing B cell inactivation by HIV. It is said that it is. Phase I clinical trials have been in preparation since July 2021, and subjects were recruited in August 2021. And, under the auspices of the Bill & Melinda Gates Foundation, founded by Microsoft co-founder Bill Gates, the first HIV in collaboration with the Scripps Research Institute at George Washington University School of Medicine on January 27, 2022. Vaccination was done.

Mark Fineberg, IAVI Representative and CEO, said, 'We are very excited to move forward in the new direction of designing HIV vaccines using Moderna's mRNA vaccine platform. The search for HIV vaccines is a long and steep road. However, new tools such as immunogens and the mRNA vaccine platform will be key to the rapid realization of urgently needed and effective HIV vaccines. '

'We are very pleased to partner with IAVI and the Bill & Melinda Gates Foundation to apply our mRNA vaccine technology to HIV,' said Stephen Hozi, President of Moderna. We believe that advancing is an important step in our mission to realize the potential of mRNA to improve people's health. '

in Science, Posted by log1i_yk